Real‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery
International Forum of Allergy & Rhinology · 2024
DOI: 10.1002/alr.23220 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Jared Silver und 4 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Rhinosinusitis, Asthma, Sinusitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.
Abstract (Originalsprache)
Background
Trial data demonstrate that mepolizumab, a humanized anti‐interleukin 5 monoclonal antibody, is effective for patients with severe asthma and comorbid chronic rhinosinusitis (CRS) with nasal polyps. This real‐world, retrospective cohort study investigated mepolizumab for US patients with severe asthma and CRS with/without sinus surgery.
Methods
IQVIA PharMetrics Plus claims data from baseline and follow‐up (12 months before and after mepolizumab initiation) were used to analyze three patient cohorts: cohort 1 (severe asthma only); cohort 2 (severe asthma + comorbid CRS without sinus surgery); and cohort 3 (severe asthma+comorbid CRS+sinus surgery), allowing for cross‐cohort comparisons.
Results
The analysis included 495, 370, and 85 patients in cohort 1, cohort 2, and cohort 3, respectively. Systemic and oral corticosteroid use was lower for all cohorts after mepolizumab initiation. In cohort 3, asthma rescue inhaler and antibiotic use were lower during follow‐up than baseline. Asthma exacerbations were reduced by 28% to 44% comparing follow‐up versus baseline, with the largest reduction in cohort 3 (ratio of incidence rate ratio [RR] vs cohort 1: 0.76; p = 0.036). Reductions in oral corticosteroid claims were greater following mepolizumab initiation for cohort 3 versus cohort 1 (RR, 0.72; p = 0.011) and cohort 2 (RR, 0.70; p < 0.01). In cohorts 1 through 3, outpatient and emergency department visits were reduced by 1 to 2 and 0.4 to 0.6 visits annually, asthma‐related and asthma exacerbation–related total costs were reduced by $387 to $2580 USD, and medical costs were reduced by $383 to $2438 USD during follow‐up.
Conclusions
Consistent with trial data, mepolizumab use in real‐world practice shows benefits across comorbid patient cohorts with more a pronounced impact in those with severe asthma+comorbid CRS + sinus surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Durham, North Carolina, USA.
- GSK, Upper Providence, Pennsylvania, USA.
- Groupe d'analyse Ltée, Montréal, Quebec, Canada.
- Analysis Group Inc, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
Förderung
- GSK
- GlaxoSmithKline
Zitieren
APA
Silver, J., Deb, A., Laliberté, F., Gao, C., & Bhattacharyya, N. (2024). Real‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23220
Vancouver
Silver J, Deb A, Laliberté F, Gao C, Bhattacharyya N. Real‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23220
BibTeX
@article{Silver2024,
author = {Silver, Jared and Deb, Arijita and Laliberté, François and Gao, Chi and Bhattacharyya, Neil},
title = {Real‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
doi = {10.1002/alr.23220}
}
EUVIMED